Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protalix BioTherapeuticsPLX +2.18%54 Gross Margin % is 60.99% as of Jun. 2026, which is 5% above its 10-year median of 58.12. GuruFocus rates PLX with a GF Score™ of 54/100 and a GF Value™ of $2.20 (Fairly Valued). The stock has 4 warning signs investors should review. Among 734 Biotechnology companies, Protalix BioTherapeutics ranks better than 58.17% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Protalix BioTherapeutics had a gross margin of 60.99% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Protalix BioTherapeutics Gross Margin % Related Terms
Protalix BioTherapeutics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLX vs GLSI, DTIL, NERV: Gross Margin % Comparison
For the Biotechnology subindustry, Protalix BioTherapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Protalix BioTherapeutics (PLX) has a Gross Margin % of 60.99% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Protalix BioTherapeutics and its competitors. This is near median its historical median of 58.12. Over the past decade, Protalix BioTherapeutics' Gross Margin % has ranged from 8.71 to 82.71. According to the industry distribution chart, Protalix BioTherapeutics ranks #307 out of 734 companies in the Biotechnology industry, placing it in the top 41.8%.
Is Protalix BioTherapeutics' Gross Margin % too high?
Protalix BioTherapeutics' current Gross Margin % of 60.99% is near median its 10-year median of 58.12. Over the past 10 years, this metric has ranged from a low of 8.71 to a high of 82.71. The Biotechnology industry median Gross Margin % is 60.92. Protalix BioTherapeutics' value of 60.99% is 0.1% above this industry median. Based on the distribution chart, Protalix BioTherapeutics ranks #307 out of 734 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Protalix BioTherapeutics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Gross Margin % compare to GLSI and DTIL?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #307 out of 734 companies for Gross Margin %. This puts Protalix BioTherapeutics in the upper half of its industry. The industry median Gross Margin % is 60.92. Protalix BioTherapeutics' value of 60.99% is 0.1% above this benchmark. Historically, Protalix BioTherapeutics' own Gross Margin % has ranged from 8.71 to 82.71 over the past decade. While the company's 10-year median is 58.12 vs. the industry median of 60.92, Protalix BioTherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protalix BioTherapeutics's current Gross Margin % of 60.99% is 0.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Protalix BioTherapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protalix BioTherapeutics's current Gross Margin % is 60.99%, which is near median its own 10-year median of 58.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Fairly Valued. The stock's GF Value™ is $2.20, compared to a current price of $2.34 — trading 6.4% above its estimated fair value. The current Gross Margin % is 60.99%, which is near median its 10-year median of 58.12 and 0.1% above the Biotechnology industry median of 60.92. Protalix BioTherapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current Gross Margin % is 60.99% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (PLX) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of $2.34 is trading 6.4% above its estimated GF Value™ of $2.20.
GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.
Key valuation signals for PLX:
Gross Margin %: 60.99% (near median its 10-year median of 58.12)
GF Value™: $2.20 vs. price of $2.34 (6.4% above fair value)
Industry Position: 0.1% above the Biotechnology median (#307 of 734)
No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score
Get the complete analysis for PLX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLX has been successfully added to your 
